<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00806442</url>
  </required_header>
  <id_info>
    <org_study_id>2008p001696</org_study_id>
    <secondary_id>P50AT002782</secondary_id>
    <nct_id>NCT00806442</nct_id>
  </id_info>
  <brief_title>Treatment of Bronchial Asthma With Borage and Echium Seed Oils</brief_title>
  <official_title>Treatment of Bronchial Asthma With Borage and Echium Seed Oils</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Complementary and Integrative Health (NCCIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this trial is to determine the efficacy of a combination of two botanicals oils,
      borage seed oil and echium seed oil, as a potential treatment for bronchial asthma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Leukotrienes are important in the pathogenesis of inflammation, and leukotriene modifying
      drugs are now an established treatment for bronchial asthma and rhinitis. Drugs that inhibit
      the biosynthesis of leukotrienes are likely to be more effective than the currently available
      drugs that antagonize a single leukotriene receptor. Dietary supplementation with gamma
      linolenic acid (GLA) in borage seed oil provides effective inhibition of leukotriene
      generation but also increases circulating free arachidonic acid (AA), which has
      pro-inflammatory potential. The n-3 fatty acid, eicosapentaenoic acid (EPA), prevented the
      conversion of GLA to AA. However, EPA is extracted from fish oil, is not well-tolerated due
      to its taste, and at higher doses appeared to blunt the inhibition of leukotriene
      biosynthesis by GLA. Stearidonic acid (SDA) is a precursor of EPA that is extracted from
      Echium plantagineum; it is converted to EPA in humans and it does not have the organoleptic
      properties of EPA.

      We recently completed a dose-ranging study in which we determined the dose of SDA that is
      sufficient to inhibit the rise in circulating levels of arachidonic acid while maintaining
      effective inhibition of leukotriene generation.

      The goal of the present study is to test the efficacy of dietary supplementation with GLA and
      SDA (provided in borage seed oil and echium seed oil) in treating bronchial asthma.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Forced expiratory volume in 1 second (FEV1) in plant seed oil vs. placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Positive FEV1 Percent Predicted Change Among C Allele Carriers and A Homozygotes</measure>
    <time_frame>6 weeks on each treatment assignment</time_frame>
    <description>Number of participants with positive change in FEV1 % predicted (&gt;0%) among C allele carriers and A homozygotes in each arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Flow Rate (PEFR)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Morning Peak Flow Rate in plant seed oil vs. placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Rescue Use of Short Acting Beta-2 Agonists</measure>
    <time_frame>6 weeks</time_frame>
    <description>Average number of puffs of albuterol daily in plant seed oil vs. placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day-time Symptoms of Bronchial Asthma</measure>
    <time_frame>6 weeks</time_frame>
    <description>Day-time symptom scores in plant seed oil vs. placebo. 0 = Absent: No symptoms
= Mild: Symptom did not interfere with normal daily activity or sleep
= Moderate: Symptom was sufficient to interfere with normal daily activity or sleep
= Severe: Symptom was so severe as to prevent normal daily activity or sleep
These numbers were used for 1. Shortness of breath 2. Chest tightness 3. Wheezing 4. Cough 5. Phlegm/Mucus.
The total score is the sum of the 5 item scores, for a range of 0-15. A higher score represents more severe symptoms. Each participant's score is the average of varying numbers of diary cards. The treatment phase visits at 6 weeks consisted of 3 weeks of diary cards with a +/- 5 day window. The baseline visits had 2 weeks of diary cards with a +/- 5 day window. The treatment phase measures are adjusted for the baseline measures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Night-time Wakenings</measure>
    <time_frame>6 weeks</time_frame>
    <description>Average number of night-time wakenings in plant seed oil vs. placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Leukotriene Levels</measure>
    <time_frame>6 weeks</time_frame>
    <description>Urinary leukotriene levels in plant seed oil vs. placebo</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Bronchial Asthma</condition>
  <arm_group>
    <arm_group_label>1: Borage Seed Oil and Echium Seed Oil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Borage/Echium plant seed oils: 2 g/day of borage seed oil and 7 g/day of echium seed oil to provide 1.6 g/day of GLA and 0.9 g/day of SDA.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2: Placebo Comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo comparator: 9 g/day corn oil</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Borage Seed Oil and Echium Seed Oil</intervention_name>
    <description>2 g/day of borage seed oil and 7 g/day of echium seed oil to provide 1.6 g/day of GLA and 0.9 g/day of SDA.</description>
    <arm_group_label>1: Borage Seed Oil and Echium Seed Oil</arm_group_label>
    <other_name>CROSSENTIAL GLA TG40</other_name>
    <other_name>INCROMEGA V3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Corn Oil</intervention_name>
    <description>9 g/day of corn oil</description>
    <arm_group_label>2: Placebo Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of bronchial asthma

          -  Male or female 18 years to 65 years of age

          -  FEV1 50 to 90% of predicted, or personal best.

          -  Improvement of &gt;=12% FEV1 with bronchodilator

        Exclusion Criteria:

          -  Pregnant or nursing

          -  Smoking history of &gt; 10 pack years or active smoking within the past year.

          -  Due to possible effects on leukotriene biosynthesis, use of the following asthma
             treatments within the preceding month will be exclusion criteria:

               -  leukotriene modifying drugs,

               -  theophylline

               -  oral steroids.

               -  dietary supplements with fatty acids or other products that may interfere with
                  leukotriene generation.

          -  Treatment within the previous three months with omalizumab (monoclonal antibody
             directed against IgE)

          -  Subjects will not be permitted to take non-steroidal anti-inflammatory drugs in the
             week prior to any measurements of ex vivo leukotriene generation because of their
             effects on leukotriene biosynthesis via inhibition of prostaglandin generation.

          -  A history of aspirin-sensitive asthma

          -  Significant abnormalities in CBC, differential white cell count, renal function, and
             liver function, or urinalysis.

          -  Any serious co-morbid medical condition.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elliot Israel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asthma Research Center, Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://asthmabwh.org</url>
    <description>Asthma Research Center, Brigham and Women's Hospital</description>
  </link>
  <reference>
    <citation>James MJ, Ursin VM, Cleland LG. Metabolism of stearidonic acid in human subjects: comparison with the metabolism of other n-3 fatty acids. Am J Clin Nutr. 2003 May;77(5):1140-5.</citation>
    <PMID>12716664</PMID>
  </reference>
  <reference>
    <citation>Chilton-Lopez, Surette ME, Swan DD, Fonteh AN, Johnson MM, Chilton FH. Metabolism of gammalinolenic acid in human neutrophils. J Immunol. 1996 Apr 15;156(8):2941-7.</citation>
    <PMID>8609415</PMID>
  </reference>
  <reference>
    <citation>Johnson MM, Swan DD, Surette ME, Stegner J, Chilton T, Fonteh AN, Chilton FH. Dietary supplementation with gamma-linolenic acid alters fatty acid content and eicosanoid production in healthy humans. J Nutr. 1997 Aug;127(8):1435-44.</citation>
    <PMID>9237935</PMID>
  </reference>
  <reference>
    <citation>Barham JB, Edens MB, Fonteh AN, Johnson MM, Easter L, Chilton FH. Addition of eicosapentaenoic acid to gamma-linolenic acid-supplemented diets prevents serum arachidonic acid accumulation in humans. J Nutr. 2000 Aug;130(8):1925-31.</citation>
    <PMID>10917903</PMID>
  </reference>
  <reference>
    <citation>Surette ME, Koumenis IL, Edens MB, Tramposch KM, Chilton FH. Inhibition of leukotriene synthesis, pharmacokinetics, and tolerability of a novel dietary fatty acid formulation in healthy adult subjects. Clin Ther. 2003 Mar;25(3):948-71.</citation>
    <PMID>12852710</PMID>
  </reference>
  <reference>
    <citation>Surette ME, Koumenis IL, Edens MB, Tramposch KM, Clayton B, Bowton D, Chilton FH. Inhibition of leukotriene biosynthesis by a novel dietary fatty acid formulation in patients with atopic asthma: a randomized, placebo-controlled, parallel-group, prospective trial. Clin Ther. 2003 Mar;25(3):972-9.</citation>
    <PMID>12852711</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2008</study_first_submitted>
  <study_first_submitted_qc>December 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2008</study_first_posted>
  <results_first_submitted>July 16, 2014</results_first_submitted>
  <results_first_submitted_qc>June 6, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 3, 2017</results_first_posted>
  <last_update_submitted>June 6, 2017</last_update_submitted>
  <last_update_submitted_qc>June 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Elliot Israel, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Fatty acids</keyword>
  <keyword>Leukotrienes</keyword>
  <keyword>Diet</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Borage oil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>43 subjects were enrolled and signed consent; however, only 39 were randomized into a treatment group. 3 subjects screen failed and 1 subject was lost to follow up prior to randomization.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>1 - Borage Seed Oil and Echium Seed Oil, Then Placebo</title>
          <description>Borage/Echium plant seed oils: 6.0 g/day borage seed oil and 6.0 g/day echium seed oil) (containing totals of ~ 1.7 g/day of GLA and 0.7 g/day of SDA) 3x day for 3 weeks followed a 3-week washout period, then Placebo (11 g/day corn oil) 3x day for 3 weeks.</description>
        </group>
        <group group_id="P2">
          <title>2 - Placebo, Then Borage Seed Oil and Echium Seed Oil</title>
          <description>Placebo (11 g of corn oil/day) 3x day for 3 weeks followed by a 3-week washout period, then Borage/Echium plant seed oils: 6.0 g/day borage seed oil and 6.0 g/day echium seed oil) (containing totals of ~ 1.7 g/day of GLA and 0.7 g/day of SDA) 3x day for 3 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>First Intervention (3 Wks)</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Washout (3 Wks)</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Second Intervention (3 Wks)</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Particpants</title>
          <description>Includes patients scheduled to receive Borage and Echium seed oil first and participants scheduled to receive placebo first.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="39"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43" lower_limit="22" upper_limit="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Age Category</title>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Gender</title>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Forced Expiratory Volume in 1 Second (FEV1)</title>
        <description>Forced expiratory volume in 1 second (FEV1) in plant seed oil vs. placebo</description>
        <time_frame>6 weeks</time_frame>
        <population>Includes participants that completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Plant Seed Oil</title>
            <description>Borage/Echium plant seed oils: 6.0 g/day borage seed oil and 6.0 g/day echium seed oil) (containing totals of ~ 1.7 g/day of GLA and 0.7 g/day of SDA)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (11 g of corn oil/day)</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in 1 Second (FEV1)</title>
          <description>Forced expiratory volume in 1 second (FEV1) in plant seed oil vs. placebo</description>
          <population>Includes participants that completed the study.</population>
          <units>liters</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.31" lower_limit="2.22" upper_limit="2.39"/>
                    <measurement group_id="O2" value="2.25" lower_limit="2.17" upper_limit="2.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Positive FEV1 Percent Predicted Change Among C Allele Carriers and A Homozygotes</title>
        <description>Number of participants with positive change in FEV1 % predicted (&gt;0%) among C allele carriers and A homozygotes in each arm</description>
        <time_frame>6 weeks on each treatment assignment</time_frame>
        <population>Patients who are C allele carriers or A homozygotes</population>
        <group_list>
          <group group_id="O1">
            <title>Plant Seed Oil</title>
            <description>Borage/Echium plant seed oils: 6.0 g/day borage seed oil and 6.0 g/day echium seed oil) (containing totals of ~ 1.7 g/day of GLA and 0.7 g/day of SDA)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (11 g of corn oil/day)</description>
          </group>
        </group_list>
        <measure>
          <title>Positive FEV1 Percent Predicted Change Among C Allele Carriers and A Homozygotes</title>
          <description>Number of participants with positive change in FEV1 % predicted (&gt;0%) among C allele carriers and A homozygotes in each arm</description>
          <population>Patients who are C allele carriers or A homozygotes</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>C-allele Carriers</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A Homozygotes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Flow Rate (PEFR)</title>
        <description>Morning Peak Flow Rate in plant seed oil vs. placebo</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Plant Seed Oil</title>
            <description>Borage/Echium plant seed oils: 6.0 g/day borage seed oil and 6.0 g/day echium seed oil) (containing totals of ~ 1.7 g/day of GLA and 0.7 g/day of SDA)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (11 g of corn oil/day)</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Flow Rate (PEFR)</title>
          <description>Morning Peak Flow Rate in plant seed oil vs. placebo</description>
          <units>liters/minute</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="337.13" lower_limit="328.43" upper_limit="345.82"/>
                    <measurement group_id="O2" value="339.34" lower_limit="330.65" upper_limit="348.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Rescue Use of Short Acting Beta-2 Agonists</title>
        <description>Average number of puffs of albuterol daily in plant seed oil vs. placebo</description>
        <time_frame>6 weeks</time_frame>
        <population>one participant is missing some data on this measure</population>
        <group_list>
          <group group_id="O1">
            <title>Plant Seed Oil</title>
            <description>Borage/Echium plant seed oils: 6.0 g/day borage seed oil and 6.0 g/day echium seed oil) (containing totals of ~ 1.7 g/day of GLA and 0.7 g/day of SDA)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (11 g of corn oil/day)</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Rescue Use of Short Acting Beta-2 Agonists</title>
          <description>Average number of puffs of albuterol daily in plant seed oil vs. placebo</description>
          <population>one participant is missing some data on this measure</population>
          <units>Avg number of puffs of albuterol daily</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.69" lower_limit="0.42" upper_limit="0.97"/>
                    <measurement group_id="O2" value="0.50" lower_limit="0.23" upper_limit="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Day-time Symptoms of Bronchial Asthma</title>
        <description>Day-time symptom scores in plant seed oil vs. placebo. 0 = Absent: No symptoms
= Mild: Symptom did not interfere with normal daily activity or sleep
= Moderate: Symptom was sufficient to interfere with normal daily activity or sleep
= Severe: Symptom was so severe as to prevent normal daily activity or sleep
These numbers were used for 1. Shortness of breath 2. Chest tightness 3. Wheezing 4. Cough 5. Phlegm/Mucus.
The total score is the sum of the 5 item scores, for a range of 0-15. A higher score represents more severe symptoms. Each participant's score is the average of varying numbers of diary cards. The treatment phase visits at 6 weeks consisted of 3 weeks of diary cards with a +/- 5 day window. The baseline visits had 2 weeks of diary cards with a +/- 5 day window. The treatment phase measures are adjusted for the baseline measures.</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Plant Seed Oil</title>
            <description>Borage/Echium plant seed oils: 6.0 g/day borage seed oil and 6.0 g/day echium seed oil) (containing totals of ~ 1.7 g/day of GLA and 0.7 g/day of SDA)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (11 g of corn oil/day)</description>
          </group>
        </group_list>
        <measure>
          <title>Day-time Symptoms of Bronchial Asthma</title>
          <description>Day-time symptom scores in plant seed oil vs. placebo. 0 = Absent: No symptoms
= Mild: Symptom did not interfere with normal daily activity or sleep
= Moderate: Symptom was sufficient to interfere with normal daily activity or sleep
= Severe: Symptom was so severe as to prevent normal daily activity or sleep
These numbers were used for 1. Shortness of breath 2. Chest tightness 3. Wheezing 4. Cough 5. Phlegm/Mucus.
The total score is the sum of the 5 item scores, for a range of 0-15. A higher score represents more severe symptoms. Each participant's score is the average of varying numbers of diary cards. The treatment phase visits at 6 weeks consisted of 3 weeks of diary cards with a +/- 5 day window. The baseline visits had 2 weeks of diary cards with a +/- 5 day window. The treatment phase measures are adjusted for the baseline measures.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.51" lower_limit="1.79" upper_limit="3.22"/>
                    <measurement group_id="O2" value="1.61" lower_limit="0.90" upper_limit="2.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Night-time Wakenings</title>
        <description>Average number of night-time wakenings in plant seed oil vs. placebo</description>
        <time_frame>6 weeks</time_frame>
        <population>one participant is missing some night-time wakening data</population>
        <group_list>
          <group group_id="O1">
            <title>Plant Seed Oil</title>
            <description>Borage/Echium plant seed oils: 6.0 g/day borage seed oil and 6.0 g/day echium seed oil) (containing totals of ~ 1.7 g/day of GLA and 0.7 g/day of SDA)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (11 g of corn oil/day)</description>
          </group>
        </group_list>
        <measure>
          <title>Night-time Wakenings</title>
          <description>Average number of night-time wakenings in plant seed oil vs. placebo</description>
          <population>one participant is missing some night-time wakening data</population>
          <units>average number of night-time wakenings</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" lower_limit="0.05" upper_limit="0.27"/>
                    <measurement group_id="O2" value="0.13" lower_limit="0.02" upper_limit="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urinary Leukotriene Levels</title>
        <description>Urinary leukotriene levels in plant seed oil vs. placebo</description>
        <time_frame>6 weeks</time_frame>
        <population>one participant was missing some urinary leukotriene data</population>
        <group_list>
          <group group_id="O1">
            <title>Plant Seed Oil</title>
            <description>Borage/Echium plant seed oils: 6.0 g/day borage seed oil and 6.0 g/day echium seed oil) (containing totals of ~ 1.7 g/day of GLA and 0.7 g/day of SDA)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (11 g of corn oil/day)</description>
          </group>
        </group_list>
        <measure>
          <title>Urinary Leukotriene Levels</title>
          <description>Urinary leukotriene levels in plant seed oil vs. placebo</description>
          <population>one participant was missing some urinary leukotriene data</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.101" lower_limit="0.085" upper_limit="0.117"/>
                    <measurement group_id="O2" value="0.088" lower_limit="0.072" upper_limit="0.105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events data were collected for one year.</time_frame>
      <desc>Adverse events data were collected for one year, from the time of first patient enrollment to the last date of adverse event resolution.</desc>
      <group_list>
        <group group_id="E1">
          <title>Plant Seed Oil</title>
          <description>Borage/Echium plant seed oils: 6.0 g/day borage seed oil and 6.0 g/day echium seed oil) (containing totals of ~ 1.7 g/day of GLA and 0.7 g/day of SDA)</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo (11 g of corn oil/day)</description>
        </group>
        <group group_id="E3">
          <title>Washout After Plant Seed Oil</title>
          <description>Washout period between first (plant seed oil) and second (placebo) treatment assignments</description>
        </group>
        <group group_id="E4">
          <title>Washout After Placebo</title>
          <description>Washout period between first (placebo) and second (plant seed oil) treatment assignments</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Wheeze</sub_title>
                <description>subject experienced phlegm, cough, and wheeze during washout phase</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Drop in Hemoglobin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>drop in hematocrit</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>stomach ache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>food poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>allergies</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>uterine fibroid</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="28"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="28"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>cough, chest tightness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>worsening asthma symptoms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>sore throat</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>bruised rib</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Elliot Israel, MD</name_or_title>
      <organization>Brigham and Women's Hospital</organization>
      <phone>617-732-2801</phone>
      <email>eisrael@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

